Baird analyst Jack Allen raised the firm’s price target on Arcellx to $52 from $40 and keeps an Outperform rating on the shares. The firm noted Arcellx announced 2Q23 financials and provided pipeline updates, including the announcement that the partial clinical hold placed on their pivotal IMMagine-1 has been lifted. They are very encouraged to the see the rapid resolution of this hold, and increased their price target to reflect their updated timelines surrounding the CART-ddBCMA launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACLX:
- Arcellx price target raised to $50 from $49 at H.C. Wainwright
- Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results
- Arcellx announces FDA lifted clinical hold for iMMagine-1 Phase 2 program
- Arcellx reports Q2 EPS (50c), consensus (31c)
- Is ACLX a Buy, Before Earnings?